# Engineered immune-driven theranostics for clinical cardiology

## TL;DR

This paper explores how nanotechnology can be used to precisely manage cardiovascular diseases by modulating immune responses and enabling real-time monitoring.

## Contribution

The paper introduces an integrated nanotheranostic paradigm for immune-driven precision management of cardiovascular diseases.

## Key findings

- Nano-technology-based theranostic platforms regulate and image immune cell activity in cardiovascular lesions.
- These systems halt disease progression and reduce secondary cardiovascular events via anti-inflammatory mechanisms.
- Dynamic visualization of immune responses enables adaptive, personalized interventions in CVDs.

## Abstract

Immunotherapy for cardiovascular diseases (CVDs) holds great promise for precision management by modulating localized immune-inflammatory responses. The interplay between focal cardiovascular pathology and panvascular disease, necessitates highly integrated therapeutic strategies. Nano-technology-based theranostic platforms address this challenge by enabling both regulation and real-time imaging of immune cell activity within cardiovascular lesions. These functional nanotherapy systems not only halt disease progression at pathological sites but also reduce secondary cardiovascular events driven by shared inflammatory mechanisms. Additionally, nanoplatform-based dynamic visualization of immune cell responses facilitates adaptive, personalized interventions. This review introduces the role of immune cells in CVDs. It summarizes recent advances in nanomaterial-based immunomodulation strategies, including mechanisms of immune regulation, enhanced imaging, and therapeutic applications in atherosclerosis, myocardial infarction, ischemic stroke, abdominal aortic aneurysm, and myocarditis. Collectively, this integrated nanotheranostic paradigm establishes a robust foundation for the next generation of cardiovascular precision medicine.